Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim ...

Ozempic has taken TikTok by storm. It’s hailed as a miracle weight loss drug that helps you shed the pounds without even ...

RBC Capital Markets initiates Corbus Pharmaceuticals at outperform, highlighting the potential of an antibody-drug conjugate ...

The Boston Globe: First Recipient Of Genetically Engineered Pig Kidney Has Died Rick Slayman, the first man to receive ...

Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24Top-line ...

Medicenna disagrees with ASCO’s decision as the AACR 2024 abstract was limited to on-going interim results whereas the ASCO ...

Fresenius Medical Care (FMS) expects a rebound in U.S. dialysis volumes despite a potential impact from Novo ...

The majority — 62 percent — said they were using the drugs to treat a chronic condition like diabetes or heart disease while ...

A poll from the health policy nonprofit KFF found that 1 in 8 adults say they’ve taken a GLP-1 agonist, the obesity and ...

One case involved a female, age 42, with a history of bipolar I disorder, post-traumatic stress disorder (PTSD), morbid ...

Gilead Sciences Inc. is aiming to capitalize on the early August 2022 buyout of privately held U.K. biotech Mirobio Ltd. with the advancement of PD-1 agonist GS-0151 into phase Ib trials for ...